Last updated on June 2019

Safety Tolerability Pharmacokinetics and Efficacy of AMG 160 in Subjects With mCRPC


Brief description of study

A study to evaluate the safety and tolerability of AMG 160 in adult subjects with metastatic castration-resistant prostate cancer (mCRPC), and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

Detailed Study Description

This is a phase I, first-in-human study to evaluate the safety and tolerability of AMG 160, a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody, in subjects with metastatic castration-resistant prostate cancer.

Clinical Study Identifier: NCT03792841

Find a site near you

Start Over

Research Site

Duarte, CA United States
  Connect »

Research Site

Camperdown, Australia
  Connect »

Research Site

Randwick, Australia
  Connect »

Research Site

Parkville, Australia
  Connect »

Research Site

Salzburg, Austria
  Connect »

Research Site

Bruxelles, Belgium
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.